Back

Prognostic importance of changes in 6-min walk test during titration of pharmacotherapy in HFrEF

21 May 2023 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Heart failure with reduced ejection fraction (HFrEF) 3 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Professor Peder Langeland Myhre

Oslo University Hospital Rikshospitalet, Oslo (Norway)

6 More presentations in this session

Presentation thumbnail
Gender difference and clinical course of atrial fibrillation in patients with non-ischaemic cardiomyopathy
Doctor I. Chung (Singapore, SG)
Abstract Slides
Presentation thumbnail
The relationship between the right ventricular function, cardiac catheterization and CPET parameters in patients with advanced heart failure
Professor R. Acar (Istanbul, TR)
Abstract Slides
Presentation thumbnail
Safety and efficacy of induced pluripotent stem cell-derived engineered human myocardium as biological ventricular assist tissue in term. heart failure (BioVAT-HF):trial design and experience at UKSH
Doctor C. Paitazoglou (Luebeck, DE)
Abstract Slides
Presentation thumbnail
The first audit in real-world titration pattern of maximisation of four pillars of heart failure therapy to target doses in Irish nurse-led clinics.
Ms C. Murphy (Wexford, IE)
Abstract Slides
Presentation thumbnail
Impact of heart failure evidence-based-therapy in hypotensive patients
Doctor A. Fonseca (Porto, PT)
Abstract Slides

Access the full session

Session thumbnail
Heart failure with reduced ejection fraction (HFrEF) 3

The Event

Event poster

Heart Failure 2023

21 May 2023 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term prognostic value of baseline measurements and change over time of 6-minute walk test in patients with heart failure - A secondary analysis from the HF-Wii study
23 May 2023
thumbnail
Congress Session
Is left ventricular ejection fraction still relevant for guideline-directed medical therapy implementation?
18 May 2025
thumbnail
Congress Presentation
Prospective study of point of care device use in NT-proBNP therapeutic monitoring: substudy of GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Trial
29 June 2021
thumbnail
Congress Presentation
Soluble transferrin receptor as a marker of tissue iron deficiency: impact on submaximal exercise capacity and functional class in patients with heart failure without systemic iron deficiency or anaem
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources